ASSOCIATION OF CISPLATIN INDUCED NEPHROTOXICITY AND OTOTOXICITY WITH HEALTH-RELATED QUALITY OF LIFE AND ECONOMIC BURDEN IN CANCER PATIENTS
Author(s)
Jayasutha Jayram, PhD1, Anupriya V, Bachelors in pharmacy2, Manickavasagam Meenakshisundaram, MBBS, MD , DM3, Pravin Kumar Muthukumaresan, Masters in Pharmacy1.
1Sri Ramachandra Institute of Higher Education and Research(DU),Porur, Chennai , Tamil Nadu, India, 2Department of Pharmacy, Sri Ramachandra Institute of Higher Education and Research(DU), Porur, Chennai , Tamil Nadu, India, 3Sri Ramachandra Medical College and Hospital (Department of Oncology), Sri Ramachandra Institute of Higher Education and Research(DU),Porur, Chennai , Tamil Nadu, India.
1Sri Ramachandra Institute of Higher Education and Research(DU),Porur, Chennai , Tamil Nadu, India, 2Department of Pharmacy, Sri Ramachandra Institute of Higher Education and Research(DU), Porur, Chennai , Tamil Nadu, India, 3Sri Ramachandra Medical College and Hospital (Department of Oncology), Sri Ramachandra Institute of Higher Education and Research(DU),Porur, Chennai , Tamil Nadu, India.
OBJECTIVES: Cisplatin is widely used in the treatment of solid malignancies; however, its clinical utility is limited by treatment-related toxicities, particularly nephrotoxicity and ototoxicity, which may adversely affect Health-Related Quality of Life (HRQoL) and increase healthcare expenditure. This study aimed to evaluate the impact of cisplatin-induced nephrotoxicity and ototoxicity on HRQoL and economic burden among cancer patients in real-world oncology setting.
METHODS: A prospective observational study was conducted from January 2025-May 2025 at the Department of Medical Oncology, Sri Ramachandra Medical Centre, Chennai, India. 42 Adult cancer patients receiving cisplatin-based chemotherapy were enrolled. Nephrotoxicity was assessed using serum creatinine, estimated glomerular filtration rate (eGFR), and creatinine clearance. Ototoxicity was evaluated using pure-tone audiometry and hearing threshold analysis. HRQoL was assessed using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Economic burden was evaluated based on direct medical costs associated with hospitalization, hydration therapy, laboratory investigations, audiometric monitoring, supportive medications, and toxicity management. Data were analyzed using IBM SPSS Statistics version 26.0.
RESULTS: Among the 42 patients enrolled, nephrotoxicity was observed in 26.2% of patients, while ototoxicity was identified in 14.3% of patients. HRQoL assessment demonstrated significant deterioration in physical functioning, social functioning, fatigue, and global health status following chemotherapy exposure. Patients with ototoxicity experienced impaired communication and reduced social interaction, whereas nephrotoxicity contributed to increased hospitalization and supportive care requirements. Increased healthcare utilization was reported (52.4%) due to renal monitoring, audiometric evaluation, and supportive care which significantly contributed to treatment-associated economic burden.
CONCLUSIONS: Cisplatin-induced nephrotoxicity and ototoxicity were significantly associated with deterioration of HRQoL and increased economic burden among cancer patients. Early toxicity monitoring and patient centered supportive care strategies are essential to improve treatment outcomes and reduce toxicity-related burden in routine oncology practice.
METHODS: A prospective observational study was conducted from January 2025-May 2025 at the Department of Medical Oncology, Sri Ramachandra Medical Centre, Chennai, India. 42 Adult cancer patients receiving cisplatin-based chemotherapy were enrolled. Nephrotoxicity was assessed using serum creatinine, estimated glomerular filtration rate (eGFR), and creatinine clearance. Ototoxicity was evaluated using pure-tone audiometry and hearing threshold analysis. HRQoL was assessed using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Economic burden was evaluated based on direct medical costs associated with hospitalization, hydration therapy, laboratory investigations, audiometric monitoring, supportive medications, and toxicity management. Data were analyzed using IBM SPSS Statistics version 26.0.
RESULTS: Among the 42 patients enrolled, nephrotoxicity was observed in 26.2% of patients, while ototoxicity was identified in 14.3% of patients. HRQoL assessment demonstrated significant deterioration in physical functioning, social functioning, fatigue, and global health status following chemotherapy exposure. Patients with ototoxicity experienced impaired communication and reduced social interaction, whereas nephrotoxicity contributed to increased hospitalization and supportive care requirements. Increased healthcare utilization was reported (52.4%) due to renal monitoring, audiometric evaluation, and supportive care which significantly contributed to treatment-associated economic burden.
CONCLUSIONS: Cisplatin-induced nephrotoxicity and ototoxicity were significantly associated with deterioration of HRQoL and increased economic burden among cancer patients. Early toxicity monitoring and patient centered supportive care strategies are essential to improve treatment outcomes and reduce toxicity-related burden in routine oncology practice.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
EPH18
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology, SDC: Sensory System Disorders (Ear, Eye, Dental, Skin), SDC: Urinary/Kidney Disorders